ERBB3 and breast carcinoma: The authors showed that these dimers were detected in 13% of breast cancers in general and in 73% of HER2+ tumors, and that the loss of p21 expression mediated through HER2-HER3 heterodimerization is associated with poor outcome for trastuzumab-treated HER2+ patients [9].